Novavax Reports Second Quarter 2019 Financial Results
Agreement with the FDA on Phase 3 non-inferiority immunogenicity study design for NanoFlu™ NanoFlu pivotal Phase 3 clinical trial expected to initiate in the third quarter of 2019 with top-line data in the first quarter of 2020 Strategic partnership …